• SPX
  • $5,996.20
  • -0.09 %
  • -$5.15
  • DJI
  • $44,056.92
  • -0.53 %
  • -$236.22
  • N225
  • $39,376.09
  • -0.4 %
  • -$157.23
  • FTSE
  • $8,025.77
  • -1.22 %
  • -$99.42
  • IXIC
  • $19,302.46
  • 0.02 %
  • $3.70
Baudax Bio, Inc. (BXRX) Stock Price, News & Analysis

Baudax Bio, Inc. (BXRX) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$0.19
Day's range
$0.19
50-day range
$0.012
Day's range
$0.033
  • Country: US
  • ISIN: US07160F4046
52 wk range
$0.19
Day's range
$0.19
  • CEO: Dr. Geraldine A. Henwood Ph.D.
  • Website: Visit Site
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -16.47
  • Piotroski Score 1.00
  • Grade Market Perform
  • Symbol (BXRX)
  • Company Baudax Bio, Inc.
  • Price $0.19
  • Changes Percentage (0%)
  • Change $0.19
  • Day Low $0.19
  • Day High $0.19
  • Year High $0.19

Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 05/09/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Neutral
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$94.13
  • Trailing P/E Ratio -0.00023159460320833
  • Forward P/E Ratio -0.00023159460320833
  • P/E Growth -0.00023159460320833
  • Net Income $-58,795,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.